换一批
换一批The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
第一作者：
Robert,Roskoski
第一单位：
Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742-8814, United States. Electronic address: rrj@brimr.org.
作者：
关键词
Axitinib: (PubMED CID: 6450551)Cabozantinib (PubMED CID: 25102847)Catalytic spineDasatinib: (PubMED CID: 3062316)Imatinib: (PubMED CID: 5291)K/E/D/DLenvatinib: (PubMED CID: 9823820)Midostaurin: (PubMED CID: 9829523)Ponatinib: (PubMed CID: 24826799)Protein kinase inhibitor classificationProtein kinase structureRegorafenib: (PubMed CID: 11167602)Sorafenib: (PubMed CID: 216239)Sunitinib: (PubMed CID: 5329102)Targeted cancer therapy
主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);人类(Humans);突变(Mutation);肿瘤(Neoplasms);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质类c-kit(Proto-Oncogene Proteins c-kit);干细胞因子(Stem Cell Factor)
DOI
10.1016/j.phrs.2018.04.020
PMID
29704617
发布时间
2021-12-04
- 浏览4
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
